Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K. Abou‐Alfa, Bruno Sangro, Yoon‐Koo Kang et al.|NEJM Evidence|2022Cited by 1.4k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Ming‐Huang Chen, Makoto Ueno et al.|The Lancet|2023Cited by 1k
Lengthening and shortening of plasma DNA in hepatocellular carcinoma patientsPeiyong Jiang, Yuk Ming Dennis Lo, Carol W. M. Chan et al.|Proceedings of the National Academy of Sciences|2015Cited by 755
Biology and significance of alpha‐fetoprotein in hepatocellular carcinomaPeter R. Galle, Andrew X. Zhu, Friedrich Foerster et al.|Liver International|2019Cited by 591
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.Ghassan K. Abou‐Alfa, Bruno Sangro, Stephen L. Chan et al.|Journal of Clinical Oncology|2022Cited by 398